Skip to main content
SpringerLink
Log in

Mastocytosis

  • Chapter
  • First Online:
Precision Molecular Pathology of Myeloid Neoplasms

Part of the book series: Molecular Pathology Library ((MPLB,volume 12))

  • 1013 Accesses

Abstract

The molecular pathology of mastocytosis revolves around mutations in the KIT gene, although the clinical and genomic heterogeneity of this disease lends additional complexity to the topic. In addition, recent analyses have uncovered other recurrent mutations, including in genes frequently mutated in other subtypes of myeloid neoplasms. In this chapter we will present an overview of the types, incidences, and consequences of various KIT mutations in mastocytosis, while also providing a summary of the further genetic complexity revealed through next generation sequencing.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 199.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Hartmann K, Escribano L, Grattan C, Brockow K, Carter MC, Alvarez-Twose I, et al. Cutaneous manifestations in patients with mastocytosis: consensus report of the European competence network on mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology. J Allergy Clin Immunol. 2016;137(1):35–45.

    Article  PubMed  Google Scholar 

  2. Georgin-Lavialle S, Lhermitte L, Dubreuil P, Chandesris MO, Hermine O, Damaj G. Mast cell leukemia. Blood. 2013;121(8):1285–95.

    Article  CAS  PubMed  Google Scholar 

  3. Valent P, Spanblochl E, Sperr WR, Sillaber C, Zsebo KM, Agis H, et al. Induction of differentiation of human mast cells from bone marrow and peripheral blood mononuclear cells by recombinant human stem cell factor (SCF)/kit ligand (KL) in long term culture. Blood. 1992;80(9):2237–45.

    CAS  PubMed  Google Scholar 

  4. Sotlar K, Escribano L, Landt O, Mohrle S, Herrero S, Torrelo A, et al. One-step detection of c-kit point mutations using peptide nucleic acid-mediated polymerase chain reaction clamping and hybridization probes. Am J Pathol. 2003;162(3):737–46.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–405.

    Article  CAS  PubMed  Google Scholar 

  6. Horny H-P, Akin C, Arber DA, Peterson L, Tefferi A, Metcalfe DD, et al. Mastocytosis. In: World Health Organization classification of tumors of haematopoietic and lymphoid tissues. 5th ed. Lyon: IARC Press; 2016.

    Google Scholar 

  7. Horny H-P, Metcalfe DD, Bennett JM, Bain BJ, Akin C, Escribano L, et al. Mastocytosis. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: IARC Press; 2008. p. 54–63.

    Google Scholar 

  8. Berezowska S, Flaig MJ, Rueff F, Walz C, Haferlach T, Krokowski M, et al. Adult-onset mastocytosis in the skin is highly suggestive of systemic mastocytosis. Mod Pathol. 2014;27(1):19–29.

    Article  CAS  PubMed  Google Scholar 

  9. Valent P, Samorapoompichi P, Sperr WR, Horny HP, Lechner K. Myelomastocytic leukemia: myeloid neoplasm characterized by partial differentiation of mast cell-lineage cells. Hematol J. 2002;3(2):90–4.

    Article  PubMed  Google Scholar 

  10. Valent P, Horny HP, Escribano L, Longley BJ, Li CY, Schwartz LB, et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res. 2001;25(7):603–25.

    Article  CAS  PubMed  Google Scholar 

  11. Arredondo A, Gotlib J, Shier L, Medeiros B, Wong K, Cherry A, et al. Myelomastocytic leukemia versus mast cell leukemia versus systemic mastocytosis associated with acute myeloid leukemia: a diagnostic challenge. Am J Hematol. 2010;85(8):600–6.

    Article  PubMed  Google Scholar 

  12. Krokowski M, Sotlar K, Krauth M-T, Fodinger M, Valent P, Horny HP. Delineation of patterns of bone marrow mast cell infiltration in systemic mastocytosis: value of CD25, correlation with subvariations of the disease and separation from mast cell hyperplasia. Am J Clin Pathol. 2005;124(4):560–8.

    Article  PubMed  Google Scholar 

  13. Reichard KK, Chen D, Pardanani A, McClure RF, Howard MT, Kurtin PJ, et al. Morphologically occult systemic mastocytosis in bone marrow: clinicopathologic features and an algorithmic approach to diagnosis. Am J Clin Pathol. 2015;144(3):493–502.

    Article  CAS  PubMed  Google Scholar 

  14. George TI, Sotlar K, Valent P, Horny H-P. Mastocytosis. In: Jaffe ES, Arber DA, Harris NL, Quintanilla-Martinez L, editors. Hematopathology. 2nd ed. Philadelphia: Elsevier; 2017. p. 911–30.

    Google Scholar 

  15. Horny H-P, Sillaber C, Menke D, Kaiserling E, Wehrmann M, Stehberger B, et al. Diagnostic value of immunostaining for tryptase in patients with mastocytosis. Am J Surg Pathol. 1998;22(9):1132–40.

    Article  CAS  PubMed  Google Scholar 

  16. Doyle LA, Sepehr GJ, Hamilton MJ, Akin C, Castells MC, Hornick JL. A clinicopathology study of 24 cases of systemic mastocytosis involving the gastrointestinal tract and assessment of mucosal mast cell density in irritable bowel syndrome and asymptomatic patients. Am J Surg Pathol. 2014;38(6):832–43.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Escribano L, Diaz-Agustin B, Lopez A, Nunez Lopez R, Garcia-Montero A, Almeida J, et al. Immunophenotypic analysis of mast cells in mastocytosis: when and how to do it. Proposals of the Spanish network on mastocytosis (REMA). Cytometry B Clin Cytom. 2004;58(1):1–8.

    Article  PubMed  Google Scholar 

  18. Escribano L, Orfao A, Diaz-Agustin B, Villarrubia J, Cervero C, Lopez A, et al. Indolent systemic mast cell disease in adults: immunophenotypic characterization of bone marrow mast cells and its diagnostic implications. Blood. 1998;91(8):2731–6.

    CAS  PubMed  Google Scholar 

  19. Morgado JM, Perbellini O, Johnson RC, Teodósio C, Matito A, Álvarez-Twose I, et al. CD30 expression by bone marrow mast cells from different diagnostic variants of systemic mastocytosis. Histopathology. 2013;63(6):780–7.

    Article  PubMed  Google Scholar 

  20. Alvarez-Twose I, Jara-Acevedo M, Morgado JM, Garcia-Montero A, Sanchez-Munoz L, Teodosio C, et al. Clinical, immunophenotypic, and molecular characteristics of well-differentiated systemic mastocytosis. J Allergy Clin Immunol. 2016;137(1):168–78.

    Article  CAS  PubMed  Google Scholar 

  21. Horny HP, Sotlar K, Stellmacher F, Krokowski M, Agis H, Schwartz LB, et al. The tryptase positive compact round cell infiltrate of the bone marrow (TROCI-BM): a novel histopathological finding requiring the application of lineage specific markers. J Clin Pathol. 2006;59(3):298–302.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Metcalfe DD. Mast cells and mastocytosis. Blood. 2008;112(4):946–56.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Bibi S, Langenfeld F, Jeanningros S, Brenet F, Soucie E, Hermine O, et al. Molecular defects in mastocytosis. Immunol Allergy Clin N Am. 2012;34(2):239–62.

    Article  Google Scholar 

  24. Laine E, Chauvot de Beauchene I, Perahia D, Auclair C, Tchertanov L. Mutation D816V alters the internal structure and dynamics of c-KIT receptor cytoplasmic region: implications for dimerization and activation mechanisms. PLoS Comput Biol. 2011;7(6):e1002068.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Xiang Z, Kreisel F, Cain J, Colson A, Tomasson MH. Neoplasia driven by mutant c-KIT is mediated by intracellular, not plasma membrane, receptor signaling. Mol Cell Biol. 2007;27(1):267–82.

    Article  CAS  PubMed  Google Scholar 

  26. Sun J, Pedersen M, Rönnstrand L. The D816V mutation of c-kit circumvents a requirement for Src family kinases in c-kit signal transduction. J Biol Chem. 2009;284(17):11039–47.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Hartmann K, Wardelmann E, Ma Y, Merkelbach–Bruse S, Preussner LM, Woolery C, et al. Novel germline mutation of KIT associated with familial gastrointestinal stromal tumors and mastocytosis. Gastroenterology. 2005;129(3):1042–6.

    Article  CAS  PubMed  Google Scholar 

  28. Zhang LY, Smith ML, Schultheis B, Fitzgibbon J, Lister TA, Melo JV, et al. A novel K509I mutation of KIT identified in familial mastocytosis—in vitro and in vivo responsiveness to imatinib therapy. Leuk Res. 2006;30(4):373–8.

    Article  CAS  PubMed  Google Scholar 

  29. De Melo Campos P, Machado-Neto JA, Scopim-Ribeiro R, Visconte V, Tabarroki A, Duarte AS, et al. Familial systemic mastocytosis with germline KIT K509I mutation is sensitive to treatment with imatinib, dastainib and PKC412. Leuk Res. 2014;38(10):1245–51.

    Article  PubMed  Google Scholar 

  30. Wang HJ, Lin ZM, Zhang J, Yin JH, Yang Y. A new germline mutation in KIT associated with diffuse cutaneous mastocytosis in a Chinese family. Clin Exp Dermatol. 2014;39(2):146–9.

    Article  PubMed  Google Scholar 

  31. Tang X, Boxer M, Drummond A, Ogston P, Hodgins M, Burden AD. A germline mutation in KIT in familial diffuse cutaneous mastocytosis. J Med Genet. 2004;41(6):e88.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Beghini A, Tibiletti M, Roversi G, Chiaravalli A, Serio G, Capella C, et al. Germline mutation in the juxtamembrane domain of the KIT gene in a family with gastrointestinal stromal tumors and urticaria pigmentosa. Cancer. 2001;92(3):657–62.

    Article  CAS  PubMed  Google Scholar 

  33. Pollard WL, Beachkofsky TM, Kobayashi TT. Novel R634W c-kit mutation identified in familial mastocytosis. Pediatr Dermatol. 2015;32(2):267–70.

    Article  PubMed  Google Scholar 

  34. Bodemer C, Hermine O, Palmerini F, Yang Y, Grandpeix-Guyodo C, Leventhal PS, et al. Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations. J Invest Dermatol. 2010;130(3):804–15.

    Article  CAS  PubMed  Google Scholar 

  35. Wasag B, Niedoszytko M, Piskorz A, Lange M, Renke J, Jassem E, et al. Novel, activating KIT-N822I mutation in familial cutaneous mastocytosis. Exp Hematol. 2011;39(8):859–65.

    Article  CAS  PubMed  Google Scholar 

  36. Wohrl S, Moritz KB, Bracher A, Fischer G, Stingl G, Loewe R. A c-kit mutation in exon 18 in familial mastocytosis. J Invest Dermatol. 2013;133(3):839–41.

    Article  PubMed  Google Scholar 

  37. Fett N, Teng J, Longley BJ. Familial urticaria pigmentosa: report of a family and review of the role of KIT mutations. Am J Dermatopathol. 2013;35(1):113–6.

    Article  PubMed  Google Scholar 

  38. Sato-Matsumura KC, Matsumura T, Koizumi H, Sato H, Nagashima K, Ohkawara A. Analysis of c-kit exon 11 and exon 17 of urticaria pigmentosa that occurred in monozygotic twin sisters. Br J Dermatol. 1999;140(6):1130–2.

    Article  CAS  PubMed  Google Scholar 

  39. de la Sotta P, Romero WA, Kramer D, Cardenas C, Gonzalez S. Cutaneous mastocytosis in twins: multiple mastocytomas and urticaria pigmentosa in two pairs of monozygotic twins. Pediatr Dermatol. 2011;28(5):585–7.

    Article  PubMed  Google Scholar 

  40. Chang A, Tung RC, Schlesinger T, Bergfeld WF, Dijkstra J, Kahn TA. Familial cutaneous mastocytosis. Pediatr Dermatol. 2001;18(4):271–6.

    Article  CAS  PubMed  Google Scholar 

  41. Fowler JF Jr, Parsley WM, Cotter PG. Familial urticaria pigmentosa. Arch Dermatol. 1986;122(1):80–1.

    Article  PubMed  Google Scholar 

  42. Clark DP, Buescher L, Havey A. Familial urticaria pigmentosa. Arch Intern Med. 1990;150(8):1742–4.

    Article  CAS  PubMed  Google Scholar 

  43. Meni C, Bruneau J, Georgin-Lavialle S, Le Sache de Peufeilhoux L, Damaj G, Hadj-Rabia S, et al. Paediatric mastocytosis: a systematic review of 1747 cases. Br J Dermatol. 2015;172(3):642–51.

    Article  CAS  PubMed  Google Scholar 

  44. Kristensen T, Vestergaard H, Møller MB. Improved detection of the KIT D816V mutation in patients with systemic mastocytosis using a quantitative and highly sensitive real-time qPCR assay. J Mol Diagn. 2011;13(2):180–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Georgin-Lavialle S, Aguilar C, Guieze R, Lhermitte L, Bruneau J, Fraitag S, et al. Mast cell sarcoma: a rare and aggressive entity--report of two cases and review of the literature. J Clin Oncol. 2013;31(6):e90–7.

    Article  PubMed  Google Scholar 

  46. Sotlar K, Colak S, Bache A, Berezowska S, Krokowski M, Bültmann B, et al. Variable presence of KITD816V in clonal haematological non-mast cell lineage diseases associated with systemic mastocytosis (SM-AHNMD). J Pathol. 2010;220(5):586–95.

    Article  CAS  PubMed  Google Scholar 

  47. Tefferi A, Levine RL, Lim KH, Abdel-Wahab O, Lasho TL, Patel J, et al. Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates. Leukemia. 2009;23(5):900–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Pardanani A, Lasho T, Elala Y, Wassie E, Finke C, Reichard KK, et al. Next-generation sequencing in systemic mastocytosis: derivation of a mutation-augmented clinical prognostic model for survival. Am J Hematol. 2016;91(9):888–93.

    Article  CAS  PubMed  Google Scholar 

  49. Soucie E, Hanssens K, Mercher T, Georgin-Lavialle S, Damaj G, Livideanu C, et al. In aggressive forms of mastocytosis, TET2 loss cooperates with c-KITD816V to transform mast cells. Blood. 2012;120(24):4846–9.

    Article  CAS  PubMed  Google Scholar 

  50. Damaj G, Joris M, Chandesris O, Hanssens K, Soucie E, Canioni D, et al. ASXL1 but not TET2 mutations adversely impact overall survival of patients suffering systemic mastocytosis with associated clonal hematologic non-mast-cell diseases. PLoS One. 2014;9(1):e85362.

    Article  PubMed  PubMed Central  Google Scholar 

  51. Jawhar M, Schwaab J, Schnittger S, Sotlar K, Horny HP, Metzgeroth G, et al. Molecular profiling of myeloid progenitor cells in multi-mutated advanced systemic mastocytosis identifies KIT D186V as a distinct and late event. Leukemia. 2015;29(5):1115–22.

    Article  CAS  PubMed  Google Scholar 

  52. Akin C. Molecular diagnosis of mast cell disorders: a paper from the 2005 William Beaumont Hospital symposium on molecular pathology. J Mol Diagn. 2006;8(4):412–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Jara-Acevedo M, Teodosio C, Sanchez-Muñoz L, Álvarez-Twose I, Mayado A, Caldas C, et al. Detection of the KIT D816V mutation in peripheral blood of systemic mastocytosis: diagnostic implications. Mod Pathol. 2015;28(8):1138–49.

    Article  CAS  PubMed  Google Scholar 

  54. Sotlar K. C-kit mutational analysis in paraffin material. Methods Mol Biol. 2013;999:59–78.

    Article  CAS  PubMed  Google Scholar 

  55. Kristensen T, Broesby-Olsen S, Vestergaard H, Bindslev-Jensen C, Møller MB. Targeted ultradeep next-generation sequencing as a method for KIT D816V mutation analysis in mastocytosis. Eur J Haematol. 2016;96(4):381–8.

    Article  CAS  PubMed  Google Scholar 

  56. Uzzaman A, Maric I, Noel P, Kettelhut BV, Metcalfe DD, Carter MC. Pediatric-onset mastocytosis: a long term clinical follow-up and correlation with bone marrow histopathology. Pediatr Blood Cancer. 2009;53(4):629–34.

    Article  PubMed  PubMed Central  Google Scholar 

  57. Castells M, Metcalfe DD, Escribano L. Diagnosis and treatment of cutaneous mastocytosis in children: practical recommendations. Am J Clin Dermatol. 2011;12(4):259–70.

    Article  PubMed  PubMed Central  Google Scholar 

  58. Valent P. Diagnosis and management of mastocytosis: an emerging challenge in applied hematology. Hematology Am Soc Hematol Educ Program. 2015;2015:98–105.

    PubMed  Google Scholar 

  59. Correia O, Duarte AF, Quirino P, Azevedo R, Delgado L. Cutaneous mastocytosis: two pediatric cases treated with topical pimecrolimus. Dermatol Online J. 2010;16(5):8.

    PubMed  Google Scholar 

  60. Brazzelli V, Grasso V, Manna G, et al. Indolent systemic mastocytosis treated with narrow-band UVB phototherapy: study of five cases. J Eur Acad Dermatol Venereol. 2012;26(4):465–9.

    Article  CAS  PubMed  Google Scholar 

  61. Prignano F, Troiano M, Lotti T. Cutaneous mastocytosis: successful treatment with narrowband ultraviolet B phototherapy. Clin Exp Dermatol. 2010;35(8):914–5.

    Article  CAS  PubMed  Google Scholar 

  62. Hartmann K, Siebenhaar F, Belloni B, Brockow K, Eben R, Hartmann B, et al. Effects of topical treatment with the raft modulator miltefosine and clobetasol in cutaneous mastocytosis: a randomized, double-blind, placebo-controlled trial. Br J Dermatol. 2010;162(1):185–90.

    Article  CAS  PubMed  Google Scholar 

  63. Paul C, Sans B, Suarez F, Casassus P, Barete S, Lanternier F, et al. Masitinib for the treatment of systemic and cutaneous mastocytosis with handicap: a phase 2a study. Am J Hematol. 2010;85(12):921–5.

    Article  CAS  PubMed  Google Scholar 

  64. Valent P, Akin C, Escribano L, Fodinger M, Hartmann K, Brockow K, et al. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Investig. 2007;37(6):435–53.

    Article  CAS  Google Scholar 

  65. Gonzalez de Olano D, Alvarez-Twose I, Esteban-Lopez MI, Sanchez-Munoz L, de Durana MD, Vega A, et al. Safety and effectiveness of immunotherapy in patients with indolent systemic mastocytosis presenting with Hymenoptera venom anaphylaxis. J Allergy Clin Immunol. 2008;121(2):519–26.

    Article  PubMed  Google Scholar 

  66. Niedoxzytko M, de Monchy J, van Doormaal JJ, Jassem E, Oude Elberink JN. Mastocytosis and insect venom allergy: diagnosis, safety and efficacy of venom immunotherapy. Allergy. 2009;64(9):1237–45.

    Article  Google Scholar 

  67. Kluin-Nelemans HC, Oldhoff JM, Van Doormaal JJ, Van ‘t Wout JW, Verhoef G, Gerrits WB, et al. Cladribine therapy for systemic mastocytosis. Blood. 2003;102(13):4270–6.

    Article  CAS  PubMed  Google Scholar 

  68. Arock M, Valent P. Pathogenesis, classification and treatment of mastocytosis: state of the art in 2010 and future perspectives. Expert Rev Hematol. 2010;3(4):497–516.

    Article  PubMed  Google Scholar 

  69. Ma Y, Zeng S, Metcalfe DD, Akin C, Dimitrijevic S, Butterfield JH, et al. The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood. 2002;99(5):1741–4.

    Article  CAS  PubMed  Google Scholar 

  70. Verstovsek S, Tefferi A, Cortes J, O’Brien S, Garcia-Manero G, Pardanani A, et al. Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis. Clin Cancer Res. 2008;14(12):3906–15.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. Gotlib J, Kluin-Nelemans HC, George TI, Akin C, Sotlar K, Hermine O, et al. Efficacy and safety of midostaurin in advanced systemic mastocytosis. N Engl J Med. 2016;374(26):2530–41.

    Article  CAS  PubMed  Google Scholar 

  72. Ustun C, Gotlib J, Popat U, Artz A, Scott B, Litzaow M, et al. Consensus opinion on allogeneic hematopoietic cell transplantation in advanced systemic mastocytosis. Biol Blood Marrow Transplant. 2016;22(8):1348–56.

    Article  PubMed  Google Scholar 

  73. Ustun C, Arock M, Kulin-Nelemans HC, Reiter A, Sperr WR, George T, et al. Advanced systemic mastocytosis: from molecular and genetic progress to clinical practice. Haematologica. 2016;101(10):1133–43.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathology, University of New Mexico School of Medicine, Albuquerque, NM, USA

    David Czuchlewski MD & Tracy I. George MD

Authors
  1. David Czuchlewski MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tracy I. George MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tracy I. George MD .

Editor information

Editors and Affiliations

  1. Department of Pathology, Florida Hospital, University of Central Florida, Orlando, Florida, USA

    Chung-Che (Jeff) Chang

  2. Department of Pathology, Stanford University, Stanford, California, USA

    Robert S. Ohgami

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG

About this chapter

Cite this chapter

Czuchlewski, D., George, T.I. (2018). Mastocytosis. In: Chang, CC., Ohgami, R. (eds) Precision Molecular Pathology of Myeloid Neoplasms. Molecular Pathology Library, vol 12. Springer, Cham. https://doi.org/10.1007/978-3-319-62146-3_9

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-62146-3_9

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-62144-9

  • Online ISBN: 978-3-319-62146-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation